Literature DB >> 29500608

Conversion surgery after S-1 plus oxaliplatin combination chemotherapy for advanced gastric cancer with multiple liver metastases.

Tsutomu Namikawa1, Sachi Tsuda2, Kazune Fujisawa2, Jun Iwabu2, Sunao Uemura2, Shigehiro Tsujii2, Hiromichi Maeda3, Hiroyuki Kitagawa2, Michiya Kobayashi3,4, Kazuhiro Hanazaki2.   

Abstract

Conversion therapy for gastric cancer is a new therapeutic concept. We report a case of a patient with advanced gastric cancer who underwent conversion surgery due to a remarkable regression of multiple liver metastases following chemotherapy. A 71-year-old man was referred to our hospital with gastric cancer. Esophagogastroduodenoscopy (EGD) revealed an irregular, nodular, ulcerated lesion in the lower third of the stomach. Analysis of biopsy specimens revealed a poorly differentiated adenocarcinoma. Abdominal contrast-enhanced computed tomography (CT) showed multiple liver mass lesions. The patient was clinically diagnosed with advanced gastric cancer with liver metastases and received S-1 plus oxaliplatin chemotherapy. After 6 cycles of chemotherapy, CT and magnetic resonance imaging showed complete resolution of the liver metastases, and EGD detected mucosal irregularities only. Since there was no evidence of further metastatic lesions in other organs, the patient underwent distal gastrectomy with D2 lymphadenectomy. The gross appearance of the surgically resected specimen showed a slightly elevated tumor measuring 4.5 × 3.5 cm. Pathological examination confirmed the diagnosis of a moderately differentiated gastric adenocarcinoma invading the muscularis propria with no lymph node metastases. The postoperative course was uneventful. The patient has continued to receive S-1 and oxaliplatin chemotherapy, and there has been no evidence of recurrence for 3 months following the operation. We propose that conversion therapy might be an effective treatment for patients with advanced gastric cancer; however, further studies and assessments are needed to confirm and establish this treatment strategy.

Entities:  

Keywords:  Adjuvant surgery; Chemotherapy; Conversion surgery; Gastrectomy; Gastric cancer; Liver metastases

Mesh:

Substances:

Year:  2018        PMID: 29500608     DOI: 10.1007/s12328-018-0842-8

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  21 in total

1.  Japanese classification of gastric carcinoma: 3rd English edition.

Authors: 
Journal:  Gastric Cancer       Date:  2011-06       Impact factor: 7.370

2.  Conversion surgery after combination chemotherapy of docetaxel, cisplatin and S-1 (DCS) for far-advanced gastric cancer.

Authors:  Hiroaki Mieno; Keishi Yamashita; Kei Hosoda; Hiromitsu Moriya; Katsuhiko Higuchi; Mizutomo Azuma; Shouko Komori; Tsutomu Yoshida; Satoshi Tanabe; Wasaburo Koizumi; Natsuya Katada; Masahiko Watanabe
Journal:  Surg Today       Date:  2017-04-01       Impact factor: 2.549

3.  Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer.

Authors:  Y Yamada; K Higuchi; K Nishikawa; M Gotoh; N Fuse; N Sugimoto; T Nishina; K Amagai; K Chin; Y Niwa; A Tsuji; H Imamura; M Tsuda; H Yasui; H Fujii; K Yamaguchi; H Yasui; S Hironaka; K Shimada; H Miwa; C Hamada; I Hyodo
Journal:  Ann Oncol       Date:  2014-10-14       Impact factor: 32.976

Review 4.  The roles of surgical oncologists in the new era: minimally invasive surgery for early gastric cancer and adjuvant surgery for metastatic gastric cancer.

Authors:  Kazuhiro Yoshida; Kazuya Yamaguchi; Naoki Okumura; Shinji Osada; Takao Takahashi; Yoshihiro Tanaka; Kazuaki Tanabe; Takahisa Suzuki
Journal:  Pathobiology       Date:  2011-11-18       Impact factor: 4.342

Review 5.  Preoperative chemotherapy with a trastuzumab-containing regimen for a patient with gastric cancer and hepatic metastases.

Authors:  Z-Y Li; F Shan; L-H Zhang; Z-D Bu; A-W Wu; X-J Wu; X-L Zong; S-X Li; X Ji; J-F Ji
Journal:  Genet Mol Res       Date:  2014-12-19

6.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

7.  Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study).

Authors:  W Koizumi; H Takiuchi; Y Yamada; N Boku; N Fuse; K Muro; Y Komatsu; A Tsuburaya
Journal:  Ann Oncol       Date:  2009-10-29       Impact factor: 32.976

8.  Metachronous liver and bone metastasis from small early gastric carcinoma without lymph node involvement: A case report.

Authors:  Tsutomu Namikawa; Mai Shiga; Kengo Ichikawa; Hiroyuki Kitagawa; Michiya Kobayashi; Kazuhiro Hanazaki
Journal:  Mol Clin Oncol       Date:  2012-12-14

9.  The long-term survival of stage IV gastric cancer patients with conversion therapy.

Authors:  Kazuya Yamaguchi; Kazuhiro Yoshida; Toshiyuki Tanahashi; Takao Takahashi; Nobuhisa Matsuhashi; Yoshihiro Tanaka; Kazuaki Tanabe; Hideki Ohdan
Journal:  Gastric Cancer       Date:  2017-06-14       Impact factor: 7.370

10.  Successful conversion surgery for gastric cancer with multiple liver metastases treated after S-1 plus cisplatin combination chemotherapy: a case report.

Authors:  Masashi Tsunematsu; Naoto Takahashi; Keishiro Murakami; Takeyuki Misawa; Tadashi Akiba; Katsuhiko Yanaga
Journal:  Surg Case Rep       Date:  2017-08-29
View more
  2 in total

1.  IMRT combined with S-1 concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: a prospective phase II study.

Authors:  Tao Lv; Yujie Wang; Dan Ou; Peiyao Liu; Songbing Qin; Lidan Liu; Pengrong Lou; Xiaoshen Wang
Journal:  Invest New Drugs       Date:  2019-01-08       Impact factor: 3.850

2.  Conversion surgery for metastatic gastric cancer at 2 years after initial diagnosis of cancer of unknown primary with metastasis of cervical lymph nodes and ovary: a case report.

Authors:  Masaki Suzuki; Hisashi Hosaka; Yasuyuki Fukai; Yasushi Mochida; Daigo Ozawa; Norimichi Kogure; Kazunosuke Yamada; Hitoshi Ojima
Journal:  Surg Case Rep       Date:  2021-03-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.